We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry (IHC) predict aggressive cancer, recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological parameters.

EMA shows positive cytoplasmic staining in the spindle cells. There are no atypical features and mitoses are sparse. The MIB1 labeling is low (less than 4%). Which of the following immunohistochemical stains best differentiates meningioma from schwannoma?

Mucin 1 (MUC1) was the first discovered transmembrane protein of the mucin family; it normally covers epithelial cells of the mucous membrane, providing lubrication and protection. However, aberrant expression of MUC1 is involved in cancer development, invasion and metastasis.

Mucin 1 (MUC1) is a cell membrane glycoprotein overexpressed in non-small cell lung cancer (NSCLC) and has been implicated in carcinogenesis of premalignant lung lesions. Thus, MUC1 has been a target of interest for vaccine strategies for lung cancer treatment and prevention.

Jun 24, 2005 · MUC1 overexpression was associated with a lower grade, smaller tumour size, a higher oestrogen receptor (ER)-positive phenotype and absence of both regional recurrence and distance metastasis.

May 20, 2013 · Increased expression as assessed by 214D4 (HR=1.26; 95% CI 1.014-1.565, p=0.04 log rank test) and MA695 (HR=1.20, 95% CI 1.042-1.605; p=0.02) was associated with improved survival. The prognostic value of depolarisation has yet to be analyzed. Conclusions: Over 93% of cases were MUC1 IHC positive.

MUC1 might be correlated with the histogenesis of lung adenocarcinoma, and its elevated expression may be an adverse prognostic indicator for the patients with stages IB NSCLC, particularly for those with non-squamous cell carcinomas.

We utilized various analytical techniques (qRT-PCR, IHC, Western blotting and underglycosylation and sialation assays) to identify changes in MUC1 expression and distribution with disease progression.

We have developed a fully allogeneic CAR-T cell therapy, called P-MUC1C-ALLO1, targeting the MUC1-C epitope that is manufactured using non-viral transposon-based integration (piggyBac® DNA Delivery System), resulting in a highly enriched T stem cell memory (TSCM) product.

MUC1, a member of the mucin family, is expressed in tumors of various human organs and may function as an antiadhesion molecule that inhibits cell-to-cell adhesion, inducing tumor metastasis, and served as a potential biomarker of tumor progression ...